リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Cancellation of outpatient appointments in patients with attention-deficit/hyperactivity disorder (本文)」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Cancellation of outpatient appointments in patients with attention-deficit/hyperactivity disorder (本文)

野村, 健介 慶應義塾大学

2022.03.07

概要

Background
Regular visit to psychiatric clinic is essential for successful treatment of any psychiatric condition including attention-deficit/hyperactivity disorder (AD/HD). However, cancellation of outpatient appointments in patients with AD/HD, which represents a significant medical loss, has not been systematically investigated to our knowledge.

Methods
A systematic chart review was conducted for patients visiting the Shimada Ryoiku medical Center for Challenged Children in Japan at the age of ≤15 years from January to December 2013. The primary outcome measure was the cancellation rate, defined as the number of missed visits divided by the number of scheduled visits. The cancellation rates during 24 months after the first visit were compared between outpatients with AD/HD and other psychiatric disorders, including pervasive developmental disorders (PDD), and developmental coordination disorders and/or communication disorders (DCD-CD). A generalized linear model with binomial distribution was used to examine factors associated with cancellation rates exclusively in the AD/HD group.

Results
We included 589 patients (mean ± SD age, 5.6 ± 3.4 years; 432 males) in the analysis. The cancellation rate in patients with AD/HD was 12.3% (95% confidence interval [CI]: 10.0– 15.1), which was significantly higher than in those with PDD (5.6%, 95% CI: 3.8–8.3) and DCD-CD (5.3%, 95% CI: 3.6–7.8). Prescriptions of osmotic-release oral system-methylphenidate (OROS-MPH) and antipsychotics were associated with fewer cancellations in AD/HD patients (odds ratios: 0.61, 95% CI: 0.39–0.95 and 0.49, 95% CI: 0.25–0.95, respectively), although these significances did not find in the subgroup analysis including only patients with ≥ 6 years old.

Conclusions
Patients with AD/HD were more likely to miss appointments compared to those with other psychiatric disorders. The impact of AD/HD medications as well as potential psychiatric symptoms of their parents or caregivers on appointment cancellations needs to be evaluated in more detail in future investigations.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Harpin V, Mazzone L, Raynaud JP, Kahle J, Hodgkins P. Long-term outcomes of ADHD: a systematic review of self-esteem and social function. J Atten Disord. 2016; 20(4):295–305. https://doi.org/10.1177/ 1087054713486516 PMID: 23698916

2. Matthews M, Nigg JT, Fair DA. Attention deficit hyperactivity disorder. Curr Top Behav Neurosci. 2014; 16:235–66. https://doi.org/10.1007/7854_2013_249 PMID: 24214656

3. Tarver J, Daley D, Sayal K. Attention-deficit hyperactivity disorder (ADHD): An updated review of the essential facts. Child Care Health Dev. 2014; 40(6):762–74. https://doi.org/10.1111/cch.12139 PMID: 24725022

4. Szatmari P. The epidemiology of attention-deficit hyperactivity disorders. Child Adolesc Psychiatr Clin N Am. 1992; 1(2):361–71.

5. Brown RT, Freeman WS, Perrin JM, Stein MT, Amler RW, Feldman HM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics. 2001; 107(3):e43. https://doi.org/10.1542/peds.107.3.e43 PMID: 11230624

6. Varni JW, Burwinkle TM. The PedsQL as a patient-reported outcome in children and adolescents with attention-deficit/hyperactivity disorder: A population-based study. Health Qual Life Outcomes. 2006;Apr 21(4):26. https://doi.org/10.1186/1477-7525-4-26 PMID: 16630344

7. Le HH, Hodgkins P, Postma MJ, Kahle J, Sikirica V, Setyawan J, et al. Economic impact of childhood/ adolescent ADHD in a European setting: The Netherlands as a reference case. Eur Child Adolesc Psychiatry. 2014; 23(7):587–98. https://doi.org/10.1007/s00787-013-0477-8 PMID: 24166532

8. Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012; 51(10):990–1002.e2. https://doi.org/10.1016/j.jaac.2012.07.008 PMID: 23021476

9. Robb JA, Sibley MH, Pelham WE, Foster EM, Molina BSG, Gnagy EM, et al. The estimated annual cost of ADHD to the U.S. education system. School Ment Health. 2011; 3(3):169–77. https://doi.org/10. 1007/s12310-011-9057-6 PMID: 25110528

10. Marcus SC, Durkin M. Stimulant adherence and academic performance in urban youth with attentiondeficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011; 50(5):480–9. https://doi.org/ 10.1016/j.jaac.2011.02.007 PMID: 21515197

11. Catala´-Lo´pez F, Hutton B, Nu´ñez-Beltra´n A, Page MJ, Ridao M, Saint-Gerons DM, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLoS One. 2017; 12(7):e0180355. https://doi.org/10.1371/journal.pone.0180355 PMID: 28700715

12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders fourth edition text revision. fourth edi. Washington, DC: American Psychiatric Association; 2010.

13. World Health Organization. International statistical classification of diseases and related health problems 10th revision 2010 version. 2010.

14. Musser ED, Hawkey E, Kachan-Liu SS, Lees P, Roullet JB, Goddard K, et al. Shared familial transmission of autism spectrum and attention-deficit/ hyperactivity disorders. J Child Psychol Psychiatry. 2014; 55(7):819–27. https://doi.org/10.1111/jcpp.12201 PMID: 24444366

15. Biederman J, Faraone S V., Keenan K, Benjamin J, Krifcher B, Moore C, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder: Patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. Arch Gen Psychiatry. 1992; 49(9):728– 38. https://doi.org/10.1001/archpsyc.1992.01820090056010 PMID: 1514878

16. Faraone S V., Biederman J. Nature, nurture, and attention deficit hyperactivity disorder. Dev Rev. 2000; 20(4):568–81.

17. Faraone SV, Biederman J, Mick E, Williamson S, Wilens T, Spencer T, et al. Family study of girls with attention deficit hyperactivity disorder. Am J Psychiatry. 2000; 157(7):1077–83. https://doi.org/10.1176/ appi.ajp.157.7.1077 PMID: 10873914

18. Faraone SV, Biederman J, Mick E, Doyle AE, Wilens T, Spencer T, et al. A family study of psychiatric comorbidity in girls and boys with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2001; 50 (8):586–92. https://doi.org/10.1016/s0006-3223(01)01146-5 PMID: 11690593

19. Armstrong RB, Damaraju C V., Ascher S, Schwarzman L, O’Neill J, Starr HL. Time course of treatment effect of OROS® methylphenidate in children with ADHD. J Atten Disord. 2012; 16(8):697–705. https:// doi.org/10.1177/1087054711425772 PMID: 22084448

20. Arabgol F, Panaghi L, Nikzad V. Risperidone versus methylphenidate in treatment of preschool children with attention-deficit hyperactivity disorder. Iran J Pediatr. 2015; 25(1):e265. https://doi.org/10.5812/ijp. 265 PMID: 26199694

21. Findling RL, Short EJ, Leskovec T, Townsend LD, Demeter CA, McNamara NK, et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008; 18 (4):347–54. https://doi.org/10.1089/cap.2007.0124 PMID: 18759644

22. Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, Weiss MD. Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: Analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health. 2011; 5:14. https://doi.org/ 10.1186/1753-2000-5-14 PMID: 21569378

23. Buitelaar J, Asherson P, Soutullo C, Colla M, Adams DH, Tanaka Y, et al. Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2015; 25(10):1611–21. https://doi.org/10.1016/j.euroneuro.2015.06. 003 PMID: 26169574

24. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: A prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004; 24 (1):30–5. https://doi.org/10.1097/01.jcp.0000104907.75206.c2 PMID: 14709944

25. Conners KC. Conners. 3rd ed. London, UK: Pearson Education; 2008.

26. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorder s. J Autism Dev Disord. 1994; 24(5):659–85. https://doi.org/10.1007/BF02172145 PMID: 7814313

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る